For best results when printing this announcement, please click on link below:

http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240328:nGNX4t4SMl&default-theme=true

– Industry veteran brings extensive clinical development experience to AVEO

Oncology leadership team as Chief Medical Officer –

– Formation of a Scientific Advisory Committee from world-renowned cancer

institutions –

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same

headline on March 25 by AVEO Pharmaceuticals, the text in the second paragraph

has been corrected to better reflect Dr. Braendle's clinical research

experience. The corrected release follows:

AVEO Oncology (“AVEO”), an LG Chem company, today announced the

appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief

Medical Officer. Dr. Braendle is a life sciences executive with experience

spanning from early drug discovery to the launch of small molecules,

biologics, radiopharmaceuticals, gene and cell therapies, and medical device

development.

Dr. Braendle brings more than twenty years of clinical research experience to

AVEO Oncology, most recently serving as Chief Development Officer of Autolus

Therapeutics Plc since July 2021, where he was responsible for all development

functions and the conduct of a pivotal program in CD-19 directed genetically

modified autologous T cell immunotherapy for adult acute lymphoblastic

leukemia, and the respective filing to the U.S. Food & Drug Administration and

European Medicines Agency.    

“We are delighted to have Dr. Braendle join the AVEO Oncology team

particularly at this important juncture as we seek to become a global top 20

oncology leader,” said Michael P. Bailey, President and Chief Executive

Officer of AVEO Oncology, an LG Chem company.  “Dr. Braendle’s

significant experience will be instrumental in our efforts to develop and

diversify our pipeline.”

Prior to his time at Autolus, Dr. Braendle held the role of Executive Vice

President, Chief Medical Officer and Global Head of Development at Sumitomo

Dainippon Pharma Oncology, where he was responsible for a full range of

development functions and progressed several early-stage, first in human

programs and late-stage programs. Prior to this, Dr. Braendle served as

President and CEO of ARUP Laboratories, a national clinical and anatomic

reference laboratory. Dr. Braendle also spent over a decade at Novartis AG,

where he served as Senior Vice President and Global Head of Companion

Diagnostics and led the company's precision medicine approach. Dr. Braendle

received his medical degree at RWTH Aachen University in Germany, followed by

specialty training in medical oncology, urology and pharmacology. Dr. Braendle

is also an associate professor at the University of Ulm, Germany.

Today, AVEO Oncology, an LG Chem company, and LG Chem Life Sciences also

announced the formation of its Scientific Advisory Committee

(“Committee”). This esteemed group of experts in oncology research and

clinical development were selected to advise and bring unique perspectives to

AVEO and LG Chem’s clinical strategy and business development initiatives.

"We are excited and privileged to have the opportunity to work with this group

of top oncology experts to help guide our drug development initiatives from

discovery through commercialization. Notably, the Committee represents key

areas of interest including gastrointestinal, genitourinary, ovarian, lung and

head and neck cancers," said Mr. Bailey.

The Scientific Advisory Committee is comprised of several leading cancer

experts, including:

Al B. Benson III, MD, FACP, FACCC, FASCO Professor of Medicine Associate Director from Cooperative Groups Robert H. Lurie Comprehensive Cancer Center of Northwestern University                               Scott Kopetz, MD, PhD Professor and Deputy Chair for Translational Research, Department of Gastrointestinal Medical Oncology Division of Cancer Medicine University of Texas MD Anderson Cancer Center          

D. Ross Camidge, MD, PhD Professor of Medicine/ Oncology Joyce Zeff Chair in Lung Cancer Director, Thoracic Oncology Faculty, Developmental Therapeutics Program University of Colorado Cancer Center, Aurora  John L. Marshall, MD Chief, Hematology and Oncology Professor of Medicine and Oncology Director, Otto J Ruesch Center for the Cure of Gastrointestinal Cancers Georgetown Lombardi Comprehensive Cancer Center  

Edward Chu, MD, MMS Director, Montefiore Einstein Cancer Center Albert Einstein College of Medicine                                                                                                            Tony S.K. Mok, BBS, FASCO Chairman, Department of Clinical Oncology LiShu Fan Professor of Clinical Oncology The Chinese University of Hong Kong                                                                

Ezra Cohen, MD, FRCPSC, FASCO Chief Medical Officer of Oncology Tempus University of California- San Diego                                                                                                     Paul G. Richardson, MD Director, Clinical Research Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute                                                                                          

Kevin J. Cullen, MD Professor of Oncology University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center University of Maryland School of Medicine                                          Joseph Tabernero, MD, PhD Head, Medical Oncology Department Director, Vall d’Hebron Institute of Oncology Professor of Medicine, UVic-UCC                                                                      

Enrique Grande, MD, PhD, Msc Director, Medical Oncology Program and Clinical Research lead MD Anderson Cancer Center Madrid                                                                                    Jan Vermorken, MD, PhD Emeritus Professor of Oncology Department of Medical Oncology                                                                                                                            

                                                                                                                                                                                                                 Antwerp University Hospital                                                                                                                                                                                    

About AVEO Pharmaceuticals, Inc.

AVEO is an oncology-focused biopharmaceutical company committed to delivering

medicines that provide a better life for patients with cancer. AVEO currently

markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients

with relapsed or refractory renal cell carcinoma (RCC) following two or more

prior systemic therapies. AVEO continues to develop FOTIVDA in immunooncology

and other novel targeted combinations in RCC and other indications, and has

other investigational programs in clinical development. AVEO became a wholly

owned subsidiary of LG Chem Life Sciences USA, Inc. on January 19, 2023. AVEO

continues to operate under the AVEO Oncology, an LG Chem company, name. For

more information, please visit www.aveooncology.com.

About LG Chem, Ltd. and LG Chem Life Sciences

LG Chem, Ltd. (LG Chem) is a leading global chemical company with a

diversified business portfolio in the key areas of petrochemicals, advanced

materials, and life sciences. The company manufactures a wide range of

products from high-value added petrochemicals to renewable plastics,

specializing in cutting-edge electronic and battery materials, as well as

drugs and vaccines to deliver differentiated solutions for its customers. LG

Chem Life Sciences develops, manufactures, and globally commercializes

pharmaceutical products, with a focus on Oncology, Immunology, and Metabolic

diseases. Our mission is to transform people’s lives through inspiring

science and leading innovation. For more information, please visit

www.lgchem.com.

Contacts Media:

John F. Kouten

JFK Communications, Inc.

jfkouten@jfkhealth.com

(908) 227-4714

Source: AVEO Pharmaceuticals, Inc.

(https://www.globenewswire.com/NewsRoom/AttachmentNg/2e9934c8-5039-41b0-8b9a-b6d083256851)

GlobeNewswire, Inc. 2024